Pliant Therapeutics, Inc.
PLRX
$1.49
$0.042.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.84% | 1.66% | 4.86% | -7.08% | 3.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.81% | 12.49% | 13.36% | 30.05% | 27.46% |
| Operating Income | 24.81% | -12.49% | -13.36% | -30.05% | -28.13% |
| Income Before Tax | 22.48% | -19.62% | -20.98% | -39.23% | -35.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.48% | -19.62% | -20.98% | -39.23% | -35.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.48% | -19.62% | -20.98% | -39.23% | -35.59% |
| EBIT | 24.81% | -12.49% | -13.36% | -30.05% | -28.13% |
| EBITDA | 24.78% | -12.74% | -13.50% | -30.16% | -28.10% |
| EPS Basic | 23.74% | -17.59% | -19.09% | -36.83% | -32.88% |
| Normalized Basic EPS | 23.73% | -17.60% | -19.10% | -36.86% | -32.87% |
| EPS Diluted | 23.74% | -17.59% | -19.09% | -36.83% | -32.88% |
| Normalized Diluted EPS | 23.73% | -17.60% | -19.10% | -36.86% | -32.87% |
| Average Basic Shares Outstanding | 1.66% | 1.73% | 1.59% | 1.75% | 2.04% |
| Average Diluted Shares Outstanding | 1.66% | 1.73% | 1.59% | 1.75% | 2.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |